Fundraising FoxPearl Diagnostics
Baltimore, US · Founded 2022 · 3 known investors
Find your way into Pearl Diagnostics
Sign up to see every warm intro you have to Pearl Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pearl Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pearl Diagnostics develops diagnostic assays for detecting fungal infections, including a urine-based test for Aspergillus. The company operates in the medical diagnostics and biotech industry.
Founders & leadership
Pearl Diagnostics was founded in 2022 by Kieren Marr and MaryAnn Shallcross.
KM
Kieren MarrCo-founder
MS
MaryAnn ShallcrossCo-founder
EG
Eric GornsteinExecutiveEric Gornstein is an Executive Officer and Director at Pearl Diagnostics, a biotech company developing diagnostic assays for fungal infections. He has prior experience in biotech/biopharma business development and commercial strategy roles at both large industry companies and startups.
Board
JC
John CammackBoard director
BS
Brad SpellbergBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$14.7M disclosed across 2 rounds · 2022–2026
▶$11.2MraisedApr 2026 · 21 investors · BiotechnologyRule 506(b)
▶$11.2MraisedApr 2026 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brad SpellbergDirector
- Eric GornsteinExecutive Officer, Director
- John CammackDirector
- Kieren MarrExecutive Officer, Director
- Offering amount
- $11.2M
- Amount sold
- $11.2M
- Minimum investment
- $56.5K
- Proceeds to insiders
- $500K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$3.5MraisedJun 2022 · 11 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJun 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kieren MarrExecutive Officer, Director
- Brad SpellbergDirector
- John CammackDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $100K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
GetlabsGetlabs provides at-home lab sample collection, sending phlebotomists to patients to draw blood and collect samples for lab tests ordered by their providers. Lab results are shared directly with the patient and the ordering provider, with support for connecting results to the Apple Health app.
PerlaraPerlara is a biopharmaceutical company that develops treatments for ultra-rare genetic diseases using yeast-based disease modeling and drug repurposing strategies. The company operates as a full-stack drug development platform serving rare disease patients and families.
Companies working in the same space as Pearl Diagnostics.
Frequently asked questions
- What does Pearl Diagnostics do?
- Pearl Diagnostics develops diagnostic assays for detecting fungal infections, including a urine-based test for Aspergillus. The company operates in the medical diagnostics and biotech industry.
- Who founded Pearl Diagnostics?
- Pearl Diagnostics was founded by Kieren Marr, MaryAnn Shallcross in 2022.
- Who are Pearl Diagnostics's investors?
- Pearl Diagnostics's investors include Maryland TEDCO, Rembrandt Venture Partners, TEDCO.
- How much funding has Pearl Diagnostics raised?
- Pearl Diagnostics has disclosed $14.7M raised across 2 rounds.
- Where is Pearl Diagnostics headquartered?
- Pearl Diagnostics is headquartered in Baltimore, US.